Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2024 Q2 | Sep 5, 2024 | Brown Capital Management Mid Company Fund | -7.9% | -3.1% | CRL, FIVN, GWRE, NTRA, PODD, TDOC | - | View | ||
| 2025 Q2 | Jul 22, 2025 | Harris Associates Concentrated Strategy | 3.9% | 3.7% | COF, COP, CRL, CRM, GOOG, ICLR, IQV, SCHW, WTW | downside protection, fundamentals, Mean reversion, valuation dispersion, Value Investing | The letter centers on intrinsic value investing amid extreme valuation dispersion between popular growth stocks and unloved franchises. Management argues that patience and concentration in discounted, high-quality businesses will be rewarded as fundamentals reassert themselves. The strategy emphasizes downside protection and long-term mean reversion rather than short-term momentum. | IQV COP GOOG COF SCHW |
View |
| 2025 Q1 | Apr 22, 2025 | Polen Capital – U.S. SMID Company Growth | -12.7% | -12.7% | ALGN, BAH, CRL, ELF, ETSY, FIX, FOXF, GLOB, GSHD, MANH, MODG, PGNY, ROAD, RVLV, SAIA, TECH, WING, YETI | - | View | ||
| 2025 Q1 | Mar 31, 2025 | ClearBridge Investments All Cap Growth | - | - | ABBV, APP, ARES, CRL | - | View | ||
| 2025 Q3 | Oct 14, 2025 | Madison Small Cap Fund | -1.6% | -6.6% | CIEN, CRL, CSL, EXP, GMS, HXL, SAIA, SHAK, SMPL | aerospace, Artificial Intelligence, Construction, industrials, small caps | The fund underperformed amid speculative excess and AI-driven momentum but reaffirms its focus on quality small caps. It highlights opportunities in industrial and aerospace companies like Hexcel and Eagle Materials, citing cyclical recovery potential. The managers reject AI hype as overblown and maintain discipline on valuation and fundamentals. | CRL EXP HXL |
View |
| 2025 Q4 | Jan 30, 2026 | Invesco Small Cap Value Fund | 6.8% | 17.6% | ACM, ARCB, COHR, CR, CRL, ENTG, EXPE, GL, GMED, HBM.TO, KBR, LITE, MKSI, NRG, PENN, SAIA, WAL, WBS | AI, Biotech, financials, healthcare, Intrinsic Value, small cap, technology, value | The fund employs an intrinsic value approach to stock selection, seeking companies significantly undervalued on an absolute basis. At quarter end, the difference between market prices and intrinsic value estimates was attractive, indicating potential long-term capital appreciation. Small-cap value stocks appear attractive relative to S&P 500 Index stocks. Following outperformance of large-cap stocks over small-cap stocks in recent years, the managers see greater long-term upside to intrinsic value in many small-caps compared to large-caps. The Russell 2000 Value Index P/E multiple has been at a historical discount compared to the S&P 500 Index P/E. The fund benefited from AI-driven growth potential in holdings like Lumentum, which rallied due to investor enthusiasm for its AI applications. ArcBest's operational efficiency and technological advancements using artificial intelligence should position the company well for demand recovery in trucking. | LITE GTLB ARCB GMED CRL |
View |
| 2025 Q4 | Jan 18, 2026 | Ariel Appreciation Fund | 3.0% | 11.1% | CRL, FDS, FISV, GNRC, GNTX, IPG, MSGE, OMC, SPHR | Automotive, Biotechnology, Data centers, Entertainment, Financial Services, mid cap, technology, value | Artificial intelligence continues to drive structural trends contributing to productivity gains and shifting competitive positioning across industries. However, the benefits are unevenly distributed, reinforcing market leadership narrowness and raising questions about performance durability. Live entertainment shows strong consumer demand with Sphere Entertainment's success with The Wizard of Oz and Madison Square Garden Entertainment's robust concert and Christmas Spectacular performance. The sector benefits from continued demand for live experiences and valuable real estate assets. Charles River Laboratories maintains its leadership position in outsourced drug development services despite moderated biotech funding and big pharma budget pressures. The company's scale and capabilities position it well for recovery as nonclinical testing remains essential for pipeline replenishment. Generac Holdings sees significant long-term growth potential in the data center market, benefiting from rising energy needs and artificial intelligence infrastructure expansion. This represents a key growth driver alongside traditional backup power solutions. | OMC FDS GNRC FISV MSGE CRL SCHR |
View |
| 2024 Q2 | Jul 31, 2024 | Ariel Appreciation Fund | 9.9% | 0.0% | CLB, CRL, GS, MAT, MIDD, SRCL, WBA | - | View | ||
| 2025 Q1 | Apr 14, 2025 | Upslope Capital Management | -5.1% | -5.1% | ATR, BARN SW, CRL, VFC | - | View | ||
| 2024 Q4 | Jan 15, 2025 | Upslope Capital Management | -7.3% | 9.4% | 7011 JP, 8697 JP, ATR, CHG LN, CME, CMPO, CRL, DPLM LN, DSFIR NA, NVT, QQ LN, TDY, VFC | - | View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | Fund Letters | Jonathan Edwards | Charles River Laboratories International | Health Care | Life Sciences Tools & Services | Bull | New York Stock Exchange | Biotech-Spending, Cro, drug development, Outsourcing, valuation discount | View Pitch |
| Jan 20, 2026 | Fund Letters | John W. Rogers | Charles River Laboratories International, Inc. | Health Care | Life Sciences Tools & Services | Bull | New York Stock Exchange | buybacks, lifesciences, Margins, Outourcing, Pipelines | View Pitch |
| Nov 29, 2025 | Fund Letters | Faraz Farzam | Charles River Laboratories International Inc. | Health Care | Life Sciences Tools & Services | Bull | NYSE | Biotech, Cro, deleveraging, growth, Margins, Outsourcing, research | View Pitch |
| Aug 13, 2025 | Seeking Alpha | Daniel Mellado | Charles River Laboratories | Health Care | Diagnostics & Research | Bear | NYSE | — | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||